Previous 10 | Next 10 |
– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with T...
– Ironwood also presented results of a separate survey of nearly 90,000 Americans that highlights the prevalence and burden of multiple GI diseases – – Preclinical data presented at DDW highlight linaclotide’s effect on visceral hypersensitivity, wh...
– Presentations feature four posters of distinction – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present seven posters – four of which have been named pos...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2021 Earnings Conference Call May 06, 2021, 08:30 ET Company Participants Meredith Kaya - VP, IR & Corporate Communications Thomas McCourt - President & Interim CEO Gina Consylman - Principal Accounting Officer, CFO, SVP & Treasurer Michael...
Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q1 2021 Earnings Call May 6, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals Inc (IRWD) Q1 2021 Earnings Call Trans...
Ironwood Pharmaceuticals (IRWD) has authorized a share buyback program of up to $150M through December 2022.Ironwood shares are unchanged in premarket trading at $10.83. For further details see: Ironwood Pharmaceuticals announces $150M share buyback
Ironwood Pharmaceuticals (IRWD): Q1 Non-GAAP EPS of $0.24 beats by $0.03; GAAP EPS of $0.25 in-line.Revenue of $88.85M (+11.1% Y/Y) misses by $2.3M.FY 2021 Guidance: U.S. LINZESS Net Sales Growth of 3% to 5%; Total Revenue of $370M-385M vs. consensus of $388.53M; Adjusted EBITD...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $150 million of its outstanding shares of common stock through Decem...
– LINZESS ® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year – –Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million – ...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...